With one approved biologic available and many more under investigation, the future of treatment for hidradenitis suppurativa looks very promising.
Adalimumab (Humira, AbbVie) enhances both health-related quality of life and work productivity in patients with moderate-to-severe hidradenitis suppurativa, according to the results of two phase 3 clinical trials.
Patients with hidradenitis suppurativa (HS) need wound care not only after surgery, to address HS scarring and tunneling from sinus tracts; they also need ongoing wound care for lesions that might be draining, says one dermatologist.
This month, we take a look at a treatment approach to hidradenitis suppurativa, the impact of atopic dermatitis on pediatric patients and a way to prevent mycosis fungoides progression.
Hidradenitis suppurativa can impact children and teens physically and emotionally. A dermatologist explains potential differences between pediatric and adult HS.
Expert dermatologist describes how to create the virtual multispecialty clinic to address the complex needs of hidradenitis suppurativa.
Nonablative lasers, which are essentially modified hair removal lasers, offer treatment benefits for HS patients with stage 1 or stage 2 disease, according to dermatologist.
TNF inhibitors adalimumab and infliximab have evidence-based efficacy for the treatment of hidradentitis suppurativa (HS). Anti-interleukin inhibitors ustekinumab and anakinra also being evaluated in small studies for treatment of HS. Antibiotics, hormones, retinoids, steroids and laser therapies directly targeting the lesions round out an effective treatment plan for HS patients.
Evidence supports combined treatments to target the many factors tied to hidradenitis suppurativa.
Researchers treated a small cohort with two anti-inflammatory drugs and saw a significant improvement in clinical manifestations of disease.
Further data showed the approach safely maintained results.